Streetbeat News

Stock Prices

ASPI

A securities class action lawsuit has been filed against ASP Isotopes Inc. in the Southern District of New York. The lawsuit is on behalf of investors who acquired ASP Isotopes securities between October 30, 2024, and November 26, 2024. The lead plaintiff deadline is February 3, 2025.

Portfolio Pulse from

December 10, 2024 | 1:00 am

BIOA

BioAge Labs (BIOA) has announced the discontinuation of its Phase 2 trial for azelaprag, a treatment for metabolic diseases, raising concerns about pre-IPO disclosures.

Portfolio Pulse from

December 10, 2024 | 1:00 am

KKR

Shares of Perpetual fell nearly 10% after Australian tax authorities reviewed its deal with KKR & Co, revealing higher liabilities and lower shareholder returns.

Portfolio Pulse from

December 10, 2024 | 1:00 am

AAAU

Gold prices remained steady during the early morning Asian session, supported by expectations of further economic stimulus from China.

Portfolio Pulse from

December 10, 2024 | 12:45 am

LEGN

Legend Biotech Corporation announced that their CARVYKTI® therapy significantly improved minimal residual disease negativity in patients with relapsed or refractory multiple myeloma compared to standard treatments. This reinforces CARVYKTI®'s clinical value and supports its overall survival benefit.

Portfolio Pulse from

December 10, 2024 | 12:45 am

TOL

Toll Brothers (TOL) reported its Q4 earnings for the quarter ended October 2024. The focus is on how its revenue and EPS compared to Wall Street estimates and the previous year's figures.

Portfolio Pulse from

December 10, 2024 | 12:45 am

JNJ

Johnson & Johnson's CARVYKTI® (ciltacabtagene autoleucel) has shown significantly higher rates of minimal residual disease (MRD) negativity in the CARTITUDE-4 study for multiple myeloma patients, compared to standard therapies. This adds to its overall survival benefits, making it a promising cell therapy.

Portfolio Pulse from

December 10, 2024 | 12:45 am

AUTL

Autolus Therapeutics presented promising clinical data at the ASH Annual Meeting 2024, highlighting the effectiveness of their obe-cel treatment in achieving deep molecular remission in adult ALL patients.

Portfolio Pulse from

December 10, 2024 | 12:45 am

KROS

Keros Therapeutics presented new clinical data from its Phase 2 trials of elritercept at the ASH Annual Meeting, focusing on treatments for myelodysplastic syndromes and myelofibrosis.

Portfolio Pulse from

December 10, 2024 | 12:45 am

JBL

Jabil (JBL) experienced a larger drop than the general market, closing at $134.27, a -1.01% change from the previous day.

Portfolio Pulse from

December 10, 2024 | 12:30 am